Clinically, women who require augmentation of labor are at increased risk of PPH due to their greater exposure to oxytocin in both duration and dose through exogenous administration, presumably mediated by OTR desensitization. In current practice, upon diagnosis of failure to progress during labor augmentation, oxytocin administration is discontinued, and as long as there is no indication for immediate delivery, there is a variable duration to proceed to CD. Due to the high likelihood of OTR desensitization in this patient population, it would be clinically relevant to determine the molecular mechanisms underlying this action.